The first-ever drug based on the gene-silencing technique known as RNA interference had an underwhelming first quarter of sales — but the company that brought it to market is encouraging investors to withhold judgement.
Alnylam (ALNY) said Wednesday that the drug, Onpattro, brought in less than $500,000 during the third quarter. The company has a steep hill to climb if it is to eventually become a $1 billion blockbuster, as analysts have widely suggested it might someday.
The drug, however, has only been on the market for seven weeks so far.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.